TGFBR1
Overview
TGFBR1 encodes TGF-β receptor type I (ALK5), a serine/threonine kinase receptor that mediates TGF-β signaling. In gallbladder cancer stroma, TGFBR1 expression correlates with markers of cancer-associated fibroblast activation and stromal SEMA7A.
Alterations observed in the corpus
- Expression positively correlated with stromal SEMA7A in GBC (GSE139682 and GSE276931 datasets); part of the CAF activation signature alongside fibrillar collagens, ACTA2, PDGFRA, and TGFBR2. PMID:24997986
- TGF-β-axis alteration in pancreatic ductal adenocarcinoma, part of broader TGF-β pathway disruption (alongside TGFBR2, TGFB1, ACVR1B, ACVR1C, SMAD3, SMAD6) augmenting SMAD4 loss. PMID:25855536
Cancer types (linked)
- Gallbladder cancer (GBC): TGFBR1 is co-expressed with SEMA7A and other CAF activation markers in desmoplastic GBC stroma. PMID:24997986
Co-occurrence and mutual exclusivity
Therapeutic relevance
- No direct therapeutic targeting reported in the citing study; co-expression with SEMA7A in CAF stroma may reflect paracrine TGF-β signaling contributing to fibroblast activation.
Open questions
- Whether TGFBR1 is a driver or passenger of the desmoplastic CAF state in GBC, and its relationship to clinical outcomes, is not addressed in the citing study.
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:25855536
This page was processed by crosslinker on 2026-05-14.